TABLE 1.

Combination indexes of antiproliferative effect of IRAK1/4 Inhibitor I and lenvatinib in anaplastic thyroid cancer cells

Dose IRAK1/4 Inhibitor I (μM)	Dose lenvatinib (μM)	Effect	Combination index
8305C
1	3	0.06	0.62
	10	0.11	0.86
	30	0.45	0.92
3	3	0.08	1.01
	10	0.14	0.88
	30	0.6	0.71
10	3	0.22	0.42
	10	0.4	0.39
	30	0.7	0.58
HTC/C3
3	3	0.16	2.18
	10	0.3	0.62
	30	0.64	0.52
10	3	0.23	0.78
	10	0.39	0.44
	30	0.68	0.43
ACT‐1
3	3	0.16	0.97
	10	0.26	0.43
	30	0.39	0.23
10	3	0.22	0.56
	10	0.3	0.39
	30	0.45	0.15
8505C
3	3	0.06	3.34
	10	0.1	1.24
	30	0.67	0.54
10	3	0.09	2.9
	10	0.18	0.79
	30	0.73	0.47

Combination index > 1	Antagonistic effect
1 ≧ Combination index ≧ 0.7	Slight synergistic effect/Additive effect
0.7 > Combination index	Synergistic effect